ReviewTargeted oncology2025

A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast Cancer.

Richard S Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.